• Global Research on Coronavirus Disease (COVID-19)

WHO is gathering the latest international multilingual scientific findings and knowledge on COVID-19. This database represents a comprehensive multilingual source of current literature on the topic. While it may not be exhaustive, new research is added regularly. For further details kindly click the link below;

https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov

  • Remdesivir Clinical Trials

Gilead has initiated two Phase 3 clinical studies to evaluate the safety and efficacy of remdesivir in adults diagnosed with COVID-19 following the U.S. Food and Drug Administration’s (FDA) rapid review and acceptance of Gilead’s investigational new drug (IND) filing. These randomized, open-label, multicenter studies began enrolling patients in March 2020 and will enroll a total of approximately 1,000 patients in the initial phase of the studies, in countries with high prevalence of COVID-19. For further details kindly click the links below;

https://www.gilead.com/purpose/advancing-global-health/covid-19/remdesivir-clinical-trials

https://www.nih.gov/news-events/news-releases/nih-clinical-trial-remdesivir-treat-covid-19-begins

  • COVID-19 Breakthrough as Cambridge Company Identifies Top Ranked Drugs for Treatment

A revolutionary systems pharmacology platform powered by artificial intelligence has identified the top candidate drugs that are highly likely to be effective in treating COVID-19 disease. Five of the top-ranked drugs on the list, that have already entered clinical trials for COVID-19, include:

  1. Chloroquine, the anti-malarial drug
  2. Dexamethasone, a commonly used corticosteroid
  3. Sirolimus, an immuno-suppressant drug
  4. Tacrolimus, an immuno-suppressant drug
  5. Thalidomide, a cancer treatment drug

For further details kindly click the links below;

https://www.cambridgenetwork.co.uk/news/covid-19-breakthrough-cambridge-company-identifies-top-ranked-drugs-treatment

  • The Proceedings of the National Academies of Sciences (PNAS) just secured a major breakthrough in COVID-19 therapeutics.

In preliminary findings published in the journal PNAS, a single 200 mL dose of convalescent plasma (CP) from COVID-19 patients who recently recovered shortened the duration of symptoms, improved oxygen levels and expedited viral clearance in patients who were still suffering from the disease.

For further details kindly click the links below;

https://www.theladders.com/career-advice/this-research-may-be-a-covid-19-treatment-breakthrough

  • Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.

The drug is recommended to be included in the next version of the Guidelines for the Prevention, Diagnosis, and Treatment of Pneumonia Caused by COVID-19 issued by the National Health Commission of the People's Republic of China for treatment of COVID-19 infection in larger populations in the future.

For further details kindly click the links below;

https://www.ncbi.nlm.nih.gov/pubmed/32074550


Disclaimer of Liability: The material and information contained on this website is for general information purpose only. You should not rely upon the material or information on the website as a basis for making any business, legal or any other decision. COMSTECH is not endorsing these products or materials.

COMSTECH News & Announcements


Previous News & Announcements >>

Announcements from OIC Institutions
External News & Announcements
COMSTECH Secretariat, 33-Constitution Avenue, G-5/2, Islamabad Phone: (+92 51) 9220681 - Fax: (+92 51) 9211115 - COMSTECH Primary Email    |    COMSTECH Secondary Email